CTI BioPharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CTI BioPharma and buy or sell other stocks, options, and ETFs commission-free!

About CTIC

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. 

CEO
Adam R. Craig, MD, PhD
CEOAdam R. Craig, MD, PhD
Employees
128
Employees128
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1991
Founded1991
Employees
128
Employees128

CTIC Key Statistics

Market cap
1.20B
Market cap1.20B
Price-Earnings ratio
-15.78
Price-Earnings ratio-15.78
Dividend yield
Dividend yield
Average volume
4.57M
Average volume4.57M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$9.10
52 Week high$9.10
52 Week low
$4.01
52 Week low$4.01
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.